Abstract
As a class, the retinoids have many side-effects in common. A list of the most frequently observed reactions in relation to the organ systems affected is given in Table 1. Compared to most other drugs used for cancer chemotherapy, these reactions are relatively mild; however, serious and occasionally fatal reactions have occurred, particularly in patients with acute promyelocytic leukaemia (APL).
This is a preview of subscription content, log in via an institution.
Buying options
Tax calculation will be finalised at checkout
Purchases are for personal use only
Learn about institutional subscriptionsPreview
Unable to display preview. Download preview PDF.
References
Warrell RP Jr, de Thé H, Wang Z-Y, Degos L: Acute promyelocyte leukemia. N Engl J Med 1993 (329): 177–189
Lee JS, Newman RA, Lippman SM et al: Phase I evaluation of all-trans retinoic acid in adults with solid tumors. J Clin Oncol 1993 (11):959
Smith MA, Adamson PC, Balis FM et al: Phase I and pharmacokinetic evaluation of all-trans retinoic acid in pediatric patients with cancer. J Clin Oncol 1992 (10):1666–1673
Frankel SR, Eardley A, Heller G, Berman E, Warrell RP Jr: All-trans retinoic acid for acute promyelocyte leukemia: results of the New York study. Ann Intern Med 1994 (120):278–286
DiGiovanna J, Helfgott R, Gerber L et al: Extraspinal tendon and ligament calcification associated with long-term therapy with etretinate. N Engl J Med 1986 (315):1177–1182
Kilcoyne R: Effects of retinoids on bone. J Am Acad Dermatol 1988 (19):212–216
Akiyama H, Nakamura N, Nagasaka S, Sakamaki H, Onozawa Y: Hypercalcaemia due to all-trans retinoic acid. Lancet 1992 (339):308–309
Niesvizky R, Siegel D, Straus D et al: Hypercalcemia and increased serum interleukin-6 (IL-6) levels induced by all-trans retinoic acid (ATRA) in patients with multiple myeloma. Proc Am Soc Clin Oncol 1993 (12):407
Warrell RP Jr, Frankel SR, Miller WH Jr et al: Differentiation therapy of acute promyelocytic leukemia with tretinoin (all-trans retinoic acid). N Engl J Med 1991 (324): 1385–1393
Izumi T, Hatake K, Miura Y: Acute promyelocytic leukemia (letter). New Engl J Med 1994 (330): 141
Runde V, Aul C, Sudhoft T, Heyll A, Schneider W: Retinoic acid in the treatment of acute promyelocytic leukemia: Inefficacy of the 13-cis isomer and induction of complete remission by the all-trans isomer complicated by thromboembolic events. Ann Hematol 1992 (64):270–272
Koike T, Tatewaki W, Aoki A et al: Severe symptoms of hyperhistaminemia after the treatment of acute promyelocytic leukemia with tretinoin (all-trans retinoic acid). New Engl J Med 1992 (327): 385–387
Lammer EJ, Chen DT, Hoar RM et al: Retinoic acid fetopathy. N Engl J Med 1985 (313):837–841
Dai WS, LaBraico JM, Stern RS: Epidemiology of isotretinoin exposure during pregnancy. J Am Acad Dermatol 1992 (26):599–560
Jick SS, Terris BZ, Jick H: First trimester topical tretinoin and congenital disorders. Lancet 1993 (341):1181–1182
Frankel SR, Eardley A, Lauwers G, Weiss M, Warrell RP Jr: The “retinoic acid syndrome” in acute promyelocytic leukemia. Ann Intern Med 1992 (117):292–296
Vadhat L, Eardley A, Heller G, Warrell RP Jr: Leukocytosis, the retinoic acid syndrome, and early mortality in acute promyelocytic leukema: when is chemotherapy needed during remission induction with all-trans retinoic acid. Blood 1993 (82 suppl):192A
Castaigne S, Chomienne C, Fenaux P, Daniel MT, Degos L: Hyperleukocytosis during all-trans retinoic acid for acute promyelocytic leukemia. Blood 1990 (76 suppl):260a
Fenaux P, Le Dely MC, Castaigne S et al: Effect of all-trans retinoic acid in newly diagnosed acute promyelocytic leukemia: results of a multicenter randomized trial. Blood 1993 (82):3241–3249
Eardley AM, Heller G, Warrell RP Jr: Morbidity and costs of all-trans retinoic acid compared to standard chemotherapy for remission induction in acute promyelocytic leukemia. Leukemia 1994 (8):934–939
Dombret H, Sutton L, Duarte M, Daniel MT, Leblond V, Castaigne S et al: Combined therapy with all-trans retinoic acid and high-dose chemotherapy in patients with hyperleukocytic acute promyelocytic leukemia and severe visceral hemorrhage. Leukemia 1992 (6):1237–1242
Costa A, Malone W, Perloff M et al: Tolerability of the synthetic retinoid fenretinide (HPR). Eur J Cancer Clin Oncol 1989 (25):805–808
Rotmensz N, De Palo G, Formelli F et al: Long term tolerability of fenretinide (4-HPR) in breast cancer patients. Eur J Cancer 1991 (2):1127–1131
Pizzichetta M, Rossi R, Costa A et al: Lipoproteins in fenretinide (4-HPR) treated patients. Diab Nutr Metab 1992 (5):71–72
Decensi A, Torrisi R, Polizzi A et al: Effect of the synthetic retinoid fenretinide on dark-adaptation and the ocular surface. JNCI 1994 (86): 105–110
Torrisi R, Parodi S, Fontana V et al: Factors affecting plasma retinol decline during long-term administration of the synthetic retinoid Fenretinide in breast cancer patients. Cancer Epidemiol Biomarkers & Prev 1994 (3):507–510
Gross EG and Helfgott MA: Retinoids and the eye. Dermatol Clin 1992 (10):521–531
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 1995 Springer-Verlag Berlin Heidelberg
About this paper
Cite this paper
Warrell, R.P., Pastorino, U., Decensi, A. (1995). Clinical Toxicology of the Retinoids. In: Degos, L., Parkinson, D.R. (eds) Retinoids in Oncology. ESO Monographs. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-642-79706-4_6
Download citation
DOI: https://doi.org/10.1007/978-3-642-79706-4_6
Publisher Name: Springer, Berlin, Heidelberg
Print ISBN: 978-3-642-79708-8
Online ISBN: 978-3-642-79706-4
eBook Packages: Springer Book Archive